CASE REPORTSFondaparinux as anticoagulant in a pregnant woman with heparin allergyWijesiriwardana, Ajith; Lees, David AR; Lush, ChristopherAuthor Information Department of Obstetrics and Gynaecology, Cumberland Infirmary, Carlisle, UK Received 10 February, 2005 Revised 25 October, 2005 Accepted 25 October, 2005 Correspondence and requests for reprints to Ajith Wijesiriwardana, Department of Obstetrics and Gynaecology, Cumberland Infirmary, Carlisle, Cumbria CA2 7HY, UK Tel: +44 1228 814213; fax: +44 1228 814275; e-mail: [email protected] Blood Coagulation & Fibrinolysis: March 2006 - Volume 17 - Issue 2 - p 147-149 doi: 10.1097/01.mbc.0000214710.19116.40 Buy Metrics Abstract We report a patient who had a history of deep vein thrombosis in a previous pregnancy. She was treated with heparins without any reactions in the index pregnancy. Subsequently, when the patient became pregnant again, she developed an acute cutaneous reaction to the low molecular heparin enoxaparin 3 weeks after initiation of therapy. She developed a similar reaction to delteparin as well. She was therefore treated with warfarin until 36 weeks of gestation. Then she was treated with fondaparinux (Arixtra, Sanofi-Synthelabo, Paris, France) 2.5 mg daily for the remainder of the pregnancy. Delivery was at term by induction of labour. Fondaparinux was stopped on the day of the induction of labour. It was re-started 6 h post-delivery and the patient was anticoagulated with warfarin in the post-partum period. There were no bleeding tendencies or recurrences of thrombosis during fondaparinux therapy. Both mother and baby were well after delivery. © 2006 Lippincott Williams & Wilkins, Inc.